Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.49 |
| ▸ | CA1 | P00915 | 19/20 | 0.49 |
| ▸ | CA9 | Q16790 | 12/20 | 0.49 |
| ▸ | CA12 | O43570 | 11/20 | 0.49 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603706 | 0.93 | P2RX4 (0.41) | CA2CA1CA9CA12CA5A | |
| SCHEMBL4602427 | 0.93 | CA1 (0.49) | CA2CA1CA9CA12CA5A | |
| SCHEMBL4604854 | 0.88 | P2RX4 (0.47) | CA2CA1CA9CA12 | |
| SCHEMBL4604104 | 0.86 | CA2 (0.59) | CA2CA1CA9CA12CA5A | |
| SCHEMBL4603255 | 0.85 | CA1 (0.51) | CA2CA1CA9CA12CA5A | |
| SCHEMBL4604199 | 0.85 | CA2 (0.58) | CA2CA1CA9CA12CA5A | |
| SCHEMBL4603722 | 0.82 | CA1 (0.49) | CA2CA1CA9CA12CA5A | |
| SCHEMBL2639076 | 0.82 | CYP3A4 (0.42) | CA2CA1CA9CA12CA5A | |
| SCHEMBL4602585 | 0.80 | CA1 (0.58) | CA2CA1CA9CA12CA5A | |
| SCHEMBL2639016 | 0.80 | CA12 (0.42) | CA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940781-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007045573-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | claimed |
| EP-1940781-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7388111-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007045573-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, RTF1 | CA2 4750/4885CA1 4746/4885CA9 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.